Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS©)

Journal of the Peripheral Nervous System

Volumn 20, Issue 3, 2015, Pages 296-305

  Vanhoutte, Els K ^a   Faber, Catharina G ^a   Van Nes, Sonja I ^b   Cats, Elisabeth A ^c   Van Der Pol, W Ludo ^c   Gorson, Kenneth C ^d   Van Doorn, Pieter A ^b   Cornblath, David R ^e   Van Den Berg, Leonard H ^c   Merkies, Ingemar S J ^a,f  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Department of Orthopaedic Surgery   (Netherlands)

Author keywords

MMN; multifocal motor neuropathy; outcome measure; Rasch built disability scale

Indexed keywords

ADULT; AGED; ARTICLE; CONSTRUCT VALIDITY; CONVERGENT VALIDITY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DISCRIMINANT ANALYSIS; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HUMAN; INTERNAL CONSISTENCY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RASCH ANALYSIS; RASCH BUILT OVERALL DISABILITY SCALE; DAILY LIFE ACTIVITY; DISABILITY; MIDDLE AGED; MOTOR ACTIVITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYNEUROPATHIES; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTOR ACTIVITY; OUTCOME ASSESSMENT (HEALTH CARE); POLYNEUROPATHIES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84942572192     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12141     Document Type: Article

References (41)

1. Andrich D, Lyne A, Sheridan B, Luo G, (2003). Rasch Unidimensional Measurement Models (RUMM2020 Version 4.0). RUMM Laboratory, Duncraig.
2. Azulay JP, Blin O, Pouget J, Boucraut J, Bille-Turc F, Carles G, Serratrice G, (1994). Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 44: 429-432.
3. Baumann A, Hess CW, Sturzenegger M, (2009). IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J Neurol 256: 608-614.
4. Beaton DE, Boers M, Wells GA, (2002). Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol 14: 109-114.
5. Bland JM, Altman DG, (1995). Multiple significance tests: the Bonferroni method. BMJ 310: 170.
6. Bombardier C, Tugwell P, (1982). A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches. J Rheumatol 9: 753-757.
7. Cats EA, van der Pol WL, Piepers S, Notermans NC, van den Berg-Vos RM, van den Berg LH, (2008). New liquid intravenous immunoglobulin (10 % IVIg) for treatment of multifocal motor neuropathy: a prospective study of efficacy, safety and tolerability. J Neurol 255: 1598-1599.
8. Cats EA, van der Pol WL, Piepers S, Franssen H, Jacobs BC, van den Berg-Vos RM, Kuks JB, van Doorn PA, van Engelen BG, Verschuuren JJ, Wokke JH, Veldink JH, van den Berg LH, (2010). Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 75: 818-825.
9. DeVellis RF, (2006). Classical test theory. Med Care 44: S50-S59.
10. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE, (2000). Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55: 1256-1262.
11. Fisher WP, (1992). Reliability statistics. Rasch Meas Transact 6: 238.
12. Hahn AF, Beydoun SR, Lawson V, Team IiMS OM, Empson VG, Leibl H, Ngo LY, Gelmont D, Koski CL, (2013). A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 18: 321-330.
13. Hermans MC, Merkies IS, Laberge L, Blom EW, Tennant A, Faber CG, (2013). Fatigue and daytime sleepiness scale in myotonic dystrophy type 1. Muscle Nerve 47: 89-95.
14. Hobart JC, Cano SJ, Thompson AJ, (2010). Effect sizes can be misleading: is it time to change the way we measure change? J Neurol Neurosurg Psychiatry 81: 1044-1048.
15. Lai J-S, Eton DT, (2002). Clinically meaningful gaps. Rasch Meas Transact 15: 850.
16. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N, (2001). Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124: 145-153.
17. Linacre JM, (1994). Sample size and item calibration stability. Rasch Meas Transact 7, RUMM Laboratory.
18. Medical Research Council (1943). Aids to the Investigation of the Peripheral Nervous System. Her Majesty's Stationary Office, London.
19. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA, (2002). Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72: 596-601.
20. Merkies IS, van Nes SI, Hanna K, Hughes RA, Deng C, (2010). Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differ ences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry 81: 1194-1199.
21. Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E, (1997). Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 63: 765-769.
22. van Nes SI, Faber CG, Merkies IS, (2008). Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials. J Peripher Nerv Syst 13: 136-147.
23. van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, Faber CG, Merkies IS, (2011). Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76: 337-345.
24. Nobile-Orazio E, Cappellari A, Meucci N, Carpo M, Terenghi F, Bersano A, Priori A, Barbieri S, Scarlato G, (2002). Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 72: 761-766.
25. Rasch G, (1960). Probabilistic Models for Some Intelligence and Attainment Tests. University of Chicago Press, Chicago.
26. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M, (2005). Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev xxx: CD004429.
27. van Schaik IN, Bouche P, Illa I, Leger JM, Van den Bergh P, Cornblath DR, Evers EM, Hadden RD, Hughes RA, Koski CL, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA, (2006). European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 13: 802-808.
28. Streiner DL, Norman GR, (1998). Health Measurement Scales. A Practical Guide to Their Development and Use, 2nd Edn. Oxford University Press, New York.
29. Stucki G, Daltroy L, Katz JN, Johannesson M, Liang MH, (1996). Interpretation of change scores in ordinal clinical scales and health status measures: the whole may not equal the sum of the parts. J Clin Epidemiol 49: 711-717.
30. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J, (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19: 604-607.
31. Tennant A, Conaghan PG, (2007). The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper? Arthritis Rheum 57: 1358-1362.
32. Umapathi T, Hughes RA, Nobile-Orazio E, Leger JM, (2012). Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 4: CD003217.
33. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH, (2005). Multifocal motor neuropathy. Lancet Neurol 4: 309-319.
34. Van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, Jennekens FG, Wokke JH, (1995). Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59: 248-252.
35. Van den Berg LH, Franssen H, Wokke JH, (1998). The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 121 (Pt 3): 421-428.
36. Van den Berg-Vos RM, Van den Berg LH, Franssen H, Van Doorn PA, Merkies IS, Wokke JH, (2000). Treatment of multifocal motor neuropathy with interferon-beta1A. Neurology 54: 1518-1521.
37. Vanhoutte EK, Faber CG, Merkies IS, Ssg PN, (2013). 196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8-10 February 2013, Naarden, The Netherlands. Neuromuscul Disord 23: 924-933.
38. Vanhoutte EKH, Hermans MCE, Faber CG, Gorson KC, Merkies ISJ, Thonnard JL,; on behalf of the PeriNomS Study Group (2015). Rasch-ionale for neurologists. J Peripher Nerv Syst 20: 260-268.
39. W.H.O (2010). The International Classification of Functioning, Disability and Health (ICF). WHO, Geneve.
40. Wright BD, (2003). Rack and stack: time 1 vs. time 2. Rasch Meas Transact 17: 905-906.
41. Wright BD, Stone MH, (1979). Best Test Design. Media Press, Chicago.